Filing Flows › Immucell (ICCC) › Q2 2026 › vs Q2 2025
Immucell (ICCC) Q2 2026 vs Q2 2025 (year over year)
Immucell's revenue rose $741K (+12%) from $6.4M in Q2 2025 to $7.2M in Q2 2026. Gross margin 33.9% against 43.7% (-9.8 pts).
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 33.9% | 43.7% | -9.8 pts |
| Operating margin | 26.9% | 8.8% | +18.1 pts |
| Net margin | 25.5% | 7.8% | +17.7 pts |
| Free cash flow margin | 31.8% | 22.4% | +9.4 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $7.2M | $6.4M | $741K | +12% |
| Gross profit | $2.4M | $2.8M | −$381K | -14% |
| Cost of revenue | $4.7M | $3.6M | $1.1M | +31% |
| Operating profit | $1.9M | $570K | $1.4M | +240% |
| Operating expenses | $502K | $2.2M | −$1.7M | -78% |
| Pre-tax earnings | $1.9M | $504K | $1.4M | +273% |
| Other expense, net | $54K | $66K | −$11K | -17% |
| Net earnings | $1.8M | $502K | $1.3M | +266% |
| Income tax | $46K | $2K | $44K | 24× |
| Depreciation & amortization | $471K | $679K | −$208K | -31% |
| Share-based compensation | $240K | $67K | $173K | +260% |
| Working capital & other | $474K | $354K | $120K | +34% |
| Operating cash flow | $3.0M | $1.6M | $1.4M | +89% |
| Free cash flow (OCF − capex) | $2.3M | $1.4M | $839K | +58% |
| Capital expenditures | $734K | $155K | $579K | +373% |
Questions
How much did Immucell's revenue grow year over year in Q2 2026?
Immucell's revenue rose $741K (+12%) from $6.4M in Q2 2025 to $7.2M in Q2 2026. Gross margin 33.9% against 43.7% (-9.8 pts).